Format

Send to

Choose Destination
Clin Cancer Res. 2019 Jan 1;25(1):277-289. doi: 10.1158/1078-0432.CCR-18-1544. Epub 2018 Oct 12.

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.

Author information

1
Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
2
Howard Hughes Medical Institute, UT Southwestern Medical Center, Dallas, Texas.
3
Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
4
Guardant Health, Inc., Redwood, California.
5
University of Kentucky Markey Cancer Center, Lexington, Kentucky.
6
Houston Methodist Cancer Center, Houston, Texas.
7
Lurie Comprehensive Cancer Center, Chicago, Illinois.
8
Foundation Medicine, Inc., Cambridge, Massachusetts.
9
Puma Biotechnology, Inc., Los Angeles, California.
10
Department of Biophysics, UT Southwestern Medical Center, Dallas, Texas.
11
Department of Biochemistry, UT Southwestern Medical Center, Dallas, Texas.
12
Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. carlos.arteaga@utsouthwestern.edu.
13
Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
14
Harold C. Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas.

Abstract

PURPOSE:

We examined the role of ERBB2-activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer.

EXPERIMENTAL DESIGN:

ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in ERBB2 mutations in ER+ MCF7 cells and xenografts were used to investigate estrogen-independent growth. Structural analysis was used to determine the molecular interaction of HER L755S with HER3. Small molecules and siRNAs were used to inhibit PI3Kα, TORC1, and HER3.

RESULTS:

Genomic data revealed a higher rate of ERBB2 mutations in metastatic versus primary ER+ tumors. MCF7 cells with isogenically incorporated ERBB2 kinase domain mutations exhibited resistance to estrogen deprivation and to fulvestrant both in vitro and in vivo, despite maintaining inhibition of ERα transcriptional activity. Addition of the irreversible HER2 tyrosine kinase inhibitor neratinib restored sensitivity to fulvestrant. HER2-mutant MCF7 cells expressed higher levels of p-HER3, p-AKT, and p-S6 than cells with wild-type HER2. Structural analysis of the HER2 L755S variant implicated a more flexible active state, potentially allowing for enhanced dimerization with HER3. Treatment with a PI3Kα inhibitor, a TORC1 inhibitor or HER3 siRNA, but not a MEK inhibitor, restored sensitivity to fulvestrant and to estrogen deprivation. Inhibition of mutant HER2 or TORC1, when combined with fulvestrant, equipotently inhibited growth of MCF7/ERBB2 V777L xenografts, suggesting a role for TORC1 in antiestrogen resistance induced by ERBB2 mutations.

CONCLUSIONS:

ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers.

PMID:
30314968
PMCID:
PMC6320312
[Available on 2020-01-01]
DOI:
10.1158/1078-0432.CCR-18-1544

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center